{"id":30630,"date":"2025-06-20T09:32:06","date_gmt":"2025-06-20T09:32:06","guid":{"rendered":""},"modified":"-0001-11-30T00:00:00","modified_gmt":"-0001-11-30T00:00:00","slug":"challenges-in-utilizing-ai-for-rare-tumors-overcoming-data-limitations-in-precision-medicine-3354718","status":"publish","type":"post","link":"https:\/\/www.simbo.ai\/blog\/challenges-in-utilizing-ai-for-rare-tumors-overcoming-data-limitations-in-precision-medicine-3354718\/","title":{"rendered":"Challenges in Utilizing AI for Rare Tumors: Overcoming Data Limitations in Precision Medicine"},"content":{"rendered":"

Artificial intelligence (AI) is about making computer systems do tasks that usually need human brainpower. In cancer care, AI helps doctors by handling lots of medical data. It can help with accurate diagnosis, making treatment plans, and guessing patient outcomes. Two main AI methods used are machine learning (ML) and deep learning (DL). ML finds patterns in medical images or genetic data. DL uses many layers of neural networks to get better at recognizing these patterns.<\/p>\n

<\/p>\n

A review by Claudio Luchini and others found that 71 AI devices are approved by the U.S. Food and Drug Administration (FDA) for cancer use. Most of these devices focus on common cancers. Over 80% help with diagnostics, especially in cancer radiology (55%) and pathology (20%). Breast cancer uses these tools the most, with 31% of AI devices aimed at it. Lung and prostate cancers each account for 8.5%.<\/p>\n

<\/p>\n

These technologies assist doctors but do not replace traditional diagnostic methods.<\/p>\n

<\/p>\n

Rare Tumors: The Challenge of Data Scarcity<\/h2>\n

Rare tumors, like certain sarcomas or blood cancers such as some leukemias, lymphomas, and myelomas, are harder to use AI on. This is because AI needs large sets of training data. Rare tumors have fewer cases, so less data is available. This makes it hard for AI to learn the right patterns. As a result, AI is less effective at finding or predicting rare cancers.<\/p>\n

<\/p>\n

In 2023, about 184,720 new cases of blood cancers were reported in the United States. Lymphoma makes up 48% of blood cancer cases in Europe, which helps in comparison. Even though treatments have improved and more patients survive, rare tumors remain medically complex. Limited data stops the creation of reliable AI tools for diagnosis and decisions in rare cancers.<\/p>\n

<\/p>\n

Also, differences in how data is recorded and shared affect AI training. If medical records are incomplete or inconsistent, it is harder to use them for rare tumors.<\/p>\n

\n<\/p>\n

\n
\u2713<\/div>\n
\n

Automate Medical Records Requests using Voice AI Agent<\/h4>\n

SimboConnect AI Phone Agent takes medical records requests from patients instantly.<\/p>\n

Start Building Success Now <\/a>\n <\/div>\n<\/div>\n

<\/p>\n

Importance of Multi-Omics Data Integration<\/h2>\n

To make AI better at handling rare tumors, researchers say it is important to combine many types of biological data, called multi-omics. This means using DNA sequencing, RNA sequencing, protein data, and other molecular information. Together, these provide a fuller picture of cancer biology beyond images and clinical notes.<\/p>\n

<\/p>\n

Studies show that combining multi-omics data is key for understanding rare cancers. AI methods like deep learning can analyze this complex data to give personalized treatment advice and predict outcomes. However, working with multi-omics data needs strong computer power and good information management.<\/p>\n

<\/p>\n

At the Indian Institute of Technology Gandhinagar, research funded by early career awards highlights the need to make multi-omics data easy to use for AI. Clinics also need to work with software developers and data scientists to create workflows that fit both medical and technical needs.<\/p>\n

\n<\/p>\n

\n

After-hours On-call Holiday Mode Automation<\/h4>\n

SimboConnect AI Phone Agent auto-switches to after-hours workflows during closures.<\/p>\n

Secure Your Meeting \u2192<\/a>\n<\/div>\n

<\/p>\n

Data Management, Privacy, and Ethical Concerns<\/h2>\n

Good AI use needs not just lots of data, but systems that keep patient information safe during collection, storage, and sharing. Health Information Management (HIM) workers play an important role in updating and managing genomic and clinical records. These must follow strict U.S. privacy laws.<\/p>\n

<\/p>\n

The Genetic Information Nondiscrimination Act (GINA) protects patients from unfair treatment based on genetic information. This law helps encourage people to take genetic tests and join clinical studies. Ethical concerns and data biases should be controlled to stop AI systems from causing or increasing healthcare inequalities.<\/p>\n

<\/p>\n

Tools like IBM\u2019s AI Fairness 360 help find and reduce biases in data and AI models. Such control is needed to build AI systems that people can trust in sensitive areas like cancer care.<\/p>\n

<\/p>\n

Regulatory Landscape and FDA Approval<\/h2>\n

In the U.S., the FDA ensures that AI devices used in healthcare are safe and work well. When AI gets FDA approval, it shows the system is reliable to help doctors in real care settings.<\/p>\n

<\/p>\n

The approval of 71 AI devices in cancer care shows there has been progress. However, most AI tools are still focused on common cancers. FDA approval of AI using next-generation sequencing and other omics data creates a base for AI use in precision medicine.<\/p>\n

<\/p>\n

More work is needed for rare tumors because current AI mainly helps common cancers where more data is available.<\/p>\n

<\/p>\n

AI in Workflow Automation: Reducing Administrative Burden and Improving Patient Care<\/h2>\n

Besides clinical uses, AI can help with administrative work and office automation in cancer care. Precision medicine needs to handle lots of patient data, schedule visits, explain treatments, and follow up continuously.<\/p>\n

<\/p>\n

Companies like Simbo AI offer AI tools for phone automation and answering services. These tools can help medical staff reduce missed calls, manage appointments better, and improve patient experience.<\/p>\n

<\/p>\n

AI phone automation is not just a convenience. In cancer clinics, patients often need quick contact with their care teams. Automating routine calls frees staff to focus on patient care. For example, Simbo AI tools handle appointment reminders, answer questions, and manage call triage. This cuts down delays and mistakes.<\/p>\n

<\/p>\n

When connected to decision systems, AI helps patients with rare or complex tumors get timely updates on tests and treatments. This reduces workflow blocks, makes operations smoother, and helps patients stick to their care plans.<\/p>\n

<\/p>\n

Also, AI workflow tools let providers collect feedback in real time and track how engaged patients are. This data helps improve scheduling and use resources better.<\/p>\n

\n<\/p>\n

\n

Voice AI Agents Frees Staff From Phone Tag<\/h4>\n

SimboConnect AI Phone Agent handles 70% of routine calls so staff focus on complex needs.<\/p>\n

\n
\n Don\u2019t Wait \u2013 Get Started \u2192<\/a>\n <\/div>\n<\/div>\n

<\/p>\n

Collaboration Between Stakeholders: A Path Forward<\/h2>\n

Medical leaders and IT teams in the U.S. need to work together across fields to improve AI use in rare tumor care. Doctors, health information managers, software engineers, and data scientists must join efforts to:<\/p>\n

<\/p>\n

    \n
  • Improve data collection and standardize records across healthcare<\/li>\n
  • Create secure systems that protect patient privacy and use data ethically<\/li>\n
  • Support training in genomics for clinical and administrative staff<\/li>\n
  • Use AI tools that bring together clinical, genetic, and administrative data for better patient care<\/li>\n<\/ul>\n

    <\/p>\n

    The Office of the National Coordinator for Health Information Technology (ONC) works to include genetic information into health IT standards. This helps support precision medicine efforts across the country.<\/p>\n

    <\/p>\n

    Future Directions and Opportunities for U.S. Practices<\/h2>\n

    Right now, AI in cancer mostly helps common cancers. But as precision medicine grows, there is a chance to extend AI tools to rare tumors. More digital health records and multi-omics data may create bigger datasets in the future. National cancer registries and research groups can help collect rare tumor data to train AI better.<\/p>\n

    <\/p>\n

    Hospitals and clinics should invest in computer systems that can handle complex molecular and clinical data. They should also think about using AI-powered tools to reduce paperwork and improve communication between patients and doctors.<\/p>\n

    <\/p>\n

    Working with AI developers focused on cancer, like Simbo AI for patient communication, and genetic data experts can help medical practices benefit from new AI tools as they develop.<\/p>\n

    <\/p>\n

    \n

    Frequently Asked Questions<\/h2>\n
    \n
    \nWhat is the current impact of AI in oncology?<\/summary>\n
    \n

    AI is significantly reshaping oncology by improving cancer patient management, particularly in diagnostics, where it has the largest influence on clinical practice.<\/p>\n<\/p><\/div>\n<\/details>\n

    \nWhich types of cancer benefit most from AI applications?<\/summary>\n
    \n

    Breast, lung, and prostate cancers are currently experiencing the biggest advantages from AI-based devices in clinical practice.<\/p>\n<\/p><\/div>\n<\/details>\n

    \nWhat is the approval status of AI devices in clinical settings?<\/summary>\n
    \n

    Seventy-one AI-associated devices have received FDA approval for use in oncology-related fields, primarily in cancer diagnostics.<\/p>\n<\/p><\/div>\n<\/details>\n

    \nWhat are machine learning and deep learning?<\/summary>\n
    \n

    Machine learning refers to a machine’s ability to learn patterns from data, whereas deep learning is a machine learning method utilizing complex networks for enhanced prediction.<\/p>\n<\/p><\/div>\n<\/details>\n

    \nHow does AI integrate with precision oncology?<\/summary>\n
    \n

    AI integrates multi-omics data with high-performance computing and deep learning to improve cancer detection, treatment, and follow-up strategies.<\/p>\n<\/p><\/div>\n<\/details>\n

    \nWhat role does AI play in cancer diagnostics?<\/summary>\n
    \n

    AI is predominantly used as an integrative tool in cancer diagnostics, enhancing traditional methods rather than replacing them.<\/p>\n<\/p><\/div>\n<\/details>\n

    \nWhat future challenges does AI face in oncology?<\/summary>\n
    \n

    Future challenges include exploring applications beyond diagnostics, including drug discovery, therapy administration, and addressing needs for rare tumors.<\/p>\n<\/p><\/div>\n<\/details>\n

    \nHow has AI evolved since its inception?<\/summary>\n
    \n

    AI has evolved from simple rule-based systems to complex algorithms capable of mimicking human cognitive processes in various fields, including oncology.<\/p>\n<\/p><\/div>\n<\/details>\n

    \nWhat is the significance of FDA approval for AI devices?<\/summary>\n
    \n

    FDA approval signifies that AI devices meet safety and effectiveness standards for use in clinical settings, highlighting their importance in patient care.<\/p>\n<\/p><\/div>\n<\/details>\n

    \nWhat are the implications of AI for rare tumors?<\/summary>\n
    \n

    The development of AI for rare tumors remains a challenge due to the need for larger data sets, but these tumors are crucial for overall advancements in precision medicine.<\/p>\n<\/p><\/div>\n<\/details><\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

    Artificial intelligence (AI) is about making computer systems do tasks that usually need human brainpower. In cancer care, AI helps doctors by handling lots of medical data. It can help with accurate diagnosis, making treatment plans, and guessing patient outcomes. Two main AI methods used are machine learning (ML) and deep learning (DL). ML finds […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-30630","post","type-post","status-publish","format-standard","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.simbo.ai\/blog\/wp-json\/wp\/v2\/posts\/30630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.simbo.ai\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.simbo.ai\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.simbo.ai\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.simbo.ai\/blog\/wp-json\/wp\/v2\/comments?post=30630"}],"version-history":[{"count":0,"href":"https:\/\/www.simbo.ai\/blog\/wp-json\/wp\/v2\/posts\/30630\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.simbo.ai\/blog\/wp-json\/wp\/v2\/media?parent=30630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.simbo.ai\/blog\/wp-json\/wp\/v2\/categories?post=30630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.simbo.ai\/blog\/wp-json\/wp\/v2\/tags?post=30630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}